SAR 96.3
(1.05%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Operating Cash Flow | 422.75 Million | 241.02 Million | 232.11 Million | 205.86 Million | 134.46 Million | 142.39 Million |
Net Income | 301.62 Million | 309.23 Million | 180.75 Million | 236.91 Million | 109.16 Million | 149.47 Million |
Depreciation & Amortization | 36.35 Million | 38.93 Million | 36.12 Million | 36.98 Million | 34.11 Million | 27.71 Million |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | 103.37 Million | -97.14 Million | 14.01 Million | -66.04 Million | -9.38 Million | -45.03 Million |
Other non-cash items | -18.59 Million | -10 Million | 1.21 Million | -1.99 Million | 66.79 Million | 108.41 Million |
Investing Cash Flow | -21.41 Million | -11.92 Million | -28.9 Million | -2.23 Million | -23.32 Million | -35.27 Million |
Investments in PPE | -24.79 Million | -14.29 Million | -32.65 Million | -19.5 Million | -27.43 Million | -35.88 Million |
Acquisitions | 3.37 Million | 2.36 Million | 3.75 Million | 17.27 Million | 4.1 Million | 605.4 Thousand |
Investment purchases | - | - | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | 2.61 Million | 2.36 Million | 3.55 Million | 16.66 Million | 3.7 Million | -1.5 Million |
Financing Cash Flow | -263.44 Million | -203.59 Million | -137.59 Million | -203.82 Million | -123.42 Million | -206.84 Million |
Debt repayment | -30 Million | -330 Million | -3.2 Billion | -4.81 Billion | -5 Million | -1 Million |
Dividends payments | -255 Million | -195 Million | - | -158.27 Million | -120 Million | -206.08 Million |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | 21.55 Million | 321.4 Million | 3.07 Billion | 4.77 Billion | -3.78 Million | 245.38 Thousand |
Accounts receivables | -9.53 Million | -29.39 Million | -68.3 Million | -50.22 Million | 29.32 Million | -80.41 Million |
Accounts payables | 51.18 Million | 86.12 Million | 174.98 Million | -29.8 Million | 19.04 Million | 1.93 Million |
Inventory | 91.71 Million | -175.65 Million | -67 Million | -28.17 Million | -46.35 Million | 35.74 Million |
Other working capital | -30 Million | 21.77 Million | -25.66 Million | 42.17 Million | -11.39 Million | -2.29 Million |
Cash at beginning of period | 111.02 Million | 85.52 Million | 19.9 Million | 20.09 Million | 28.34 Million | 27.24 Million |
Cash at end of period | 248.92 Million | 111.02 Million | 85.52 Million | 19.9 Million | 20.09 Million | 28.34 Million |
Capital Expenditure | -24.79 Million | -14.29 Million | -32.65 Million | -19.5 Million | -27.43 Million | -35.88 Million |
Effect of forex changes on cash | - | - | - | - | 4.03 Million | - |
Net cash flow / Change in cash | 137.89 Million | 25.5 Million | 65.61 Million | -184.42 Thousand | -8.25 Million | 1.1 Million |
Free Cash Flow | 397.96 Million | 226.72 Million | 199.46 Million | 186.36 Million | 107.03 Million | 106.5 Million |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | 63.82 Million | 120.77 Million | 301.62 Million | 84.73 Million | 66.3 Million | 62.41 Million |
Depreciation & Amortization | 9.71 Million | 9.35 Million | 36.35 Million | 9.22 Million | 9.27 Million | 9.32 Million |
Deferred income taxes | - | - | - | - | - | - |
Stock-based compensation | - | - | - | - | - | - |
Change in working capital | -84.2 Million | -42.35 Million | 103.37 Million | 165.35 Million | -78.18 Million | 65.43 Thousand |
Other non-cash items | 117.72 Million | 1.44 Million | -18.59 Million | 735.9 Thousand | 717.06 Thousand | -16.3 Million |
Investing Cash Flow | -4.55 Million | -149.96 Million | -21.41 Million | -6.19 Million | -3.88 Million | -9.45 Million |
Investments in PPE | -8.37 Million | -15.86 Million | -24.79 Million | -7.18 Million | -4.6 Million | -9.48 Million |
Acquisitions | 4.13 Million | -134.1 Million | 3.37 Million | 983.11 Thousand | 727.45 Thousand | 33.92 Thousand |
Investment purchases | -316.12 Thousand | -134.1 Million | - | - | - | - |
Sales/Maturities of investments | - | - | - | - | - | - |
Other Investing Activities | 4.93 Million | -134.1 Million | 2.61 Million | 667.98 Thousand | 727.45 Thousand | -394.99 Thousand |
Financing Cash Flow | -77.53 Million | -4.35 Million | -263.44 Million | -121.2 Million | -76.4 Million | -61.78 Million |
Debt repayment | -2.53 Million | -4.35 Million | -30 Million | -1.2 Million | -1.4 Million | -1.78 Million |
Dividends payments | -75 Million | - | -255 Million | -120 Million | -75 Million | -60 Million |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | -2.53 Million | - | 21.55 Million | -1.2 Million | -1.4 Million | -1.78 Million |
Accounts receivables | 2.02 Million | -95.92 Million | -9.53 Million | 46.23 Million | -7.4 Million | 78.32 Million |
Accounts payables | -48.95 Million | 43.47 Million | 51.18 Million | 103.73 Million | -53.79 Million | -58.59 Million |
Inventory | -70.26 Million | 34.8 Million | 91.71 Million | -1.73 Million | -32.69 Million | -5.82 Million |
Other working capital | 32.98 Million | -25.39 Million | -30 Million | 17.12 Million | 15.71 Million | -13.84 Million |
Cash at beginning of period | 181.6 Million | 248.92 Million | 111.02 Million | 116.26 Million | 198.43 Million | 214.17 Million |
Cash at end of period | 69.94 Million | 181.6 Million | 248.92 Million | 248.92 Million | 116.26 Million | 198.43 Million |
Capital Expenditure | -8.37 Million | -15.86 Million | -24.79 Million | -7.18 Million | -4.6 Million | -9.48 Million |
Effect of forex changes on cash | - | - | - | - | - | - |
Net cash flow / Change in cash | -111.65 Million | -67.32 Million | 137.89 Million | 132.65 Million | -82.17 Million | -15.73 Million |
Free Cash Flow | -37.94 Million | 71.13 Million | 397.96 Million | 252.88 Million | -6.48 Million | 46.01 Million |
1448
EFIN
IIL
BPHLF
ACL
BRBR